Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eiry Roberts sold 2,632 shares of the stock in a transaction that occurred on Friday, January 8th. The stock was sold at an average price of $111.06, for a total transaction of $292,309.92. Following the completion of the transaction, the insider now owns 15,845 shares in the company, valued at approximately $1,759,745.70. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Neurocrine Biosciences stock opened at $108.15 on Thursday. The company’s fifty day moving average price is $97.98 and its 200 day moving average price is $106.30. The stock has a market capitalization of $10.10 billion, a P/E ratio of 116.29 and a beta of 1.00. Neurocrine Biosciences, Inc. has a 1 year low of $72.14 and a 1 year high of $136.26.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Saturday, November 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.11 by ($0.73). Neurocrine Biosciences had a net margin of 8.96% and a return on equity of 18.18%. The company had revenue of $258.80 million during the quarter, compared to analyst estimates of $282.59 million. During the same quarter last year, the business earned $0.56 EPS. The firm’s revenue for the quarter was up 16.5% compared to the same quarter last year. On average, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 1.28 EPS for the current fiscal year.
Several analysts have commented on the stock. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Tuesday, November 10th. Oppenheimer decreased their target price on shares of Neurocrine Biosciences from $150.00 to $145.00 in a research report on Tuesday, November 10th. Benchmark started coverage on Neurocrine Biosciences in a research report on Wednesday, September 30th. They set a “hold” rating on the stock. Wedbush decreased their price objective on Neurocrine Biosciences from $129.00 to $121.00 and set an “outperform” rating for the company in a report on Monday, December 7th. Finally, SVB Leerink lowered their target price on Neurocrine Biosciences from $120.00 to $100.00 and set a “market perform” rating on the stock in a research note on Tuesday, November 10th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $127.45.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc, a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis.
See Also: What is a support level?
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.